Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v13-EN Version v1-EN
Language English English
Date Updated 2019-03-22 2018-06-15
Drug Identification Number 02347393 02347393
Brand name MENVEO MENVEO
Common or Proper name Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM-197 Conjugate Vaccine Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM-197 Conjugate Vaccine
Company Name GLAXOSMITHKLINE INC GLAXOSMITHKLINE INC
Ingredients MENINGOCOCCAL GROUP C OLIGOSACCHARIDE CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN MENINGOCOCCAL GROUP A OLIGOSACCHARIDE MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE MENINGOCOCCAL GROUP C OLIGOSACCHARIDE CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN MENINGOCOCCAL GROUP A OLIGOSACCHARIDE MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE
Strength(s) 5MCG 47MCG 10MCG 5MCG 5MCG 5MCG 47MCG 10MCG 5MCG 5MCG
Dosage form(s) SOLUTION POWDER FOR SOLUTION SOLUTION POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1's 1's
ATC code J07AH J07AH
ATC description BACTERIAL VACCINES BACTERIAL VACCINES
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2018-06-14 2018-06-14
Estimated end date 2019-05-07 2018-12-31
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Supply unavailable in the private market. Supply available for public programs. No re-supply temporarily and remaining inventory under allocation. Supply disruptions may be seen in the private market. Menveo is available in packages of 5.
Health Canada comments